OncoMatch/Clinical Trials/NCT06360354
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Is NCT06360354 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for advanced gastrointestinal, biliary tract, and pancreatic cancers.
Treatment: Anvumetostat · Gemcitabine · Nab-paclitaxel · Modified FOLFIRINOX · RMC-6236 — The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: KRAS mutation
Required: MTAP homozygous deletion
Prior therapy
Must have received: systemic therapy — advanced or metastatic PDAC
Received at least 1 prior systemic therapy for advanced or metastatic PDAC.
Cannot have received: MAT2A inhibitor
Prior treatment with a MAT2A inhibitor
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 inhibitor
Cannot have received: MAPK pathway inhibitor
Prior treatment with a MAPK pathway inhibitor, including KRAS inhibitors
Lab requirements
Blood counts
Adequate organ function as defined in the protocol.
Kidney function
Adequate organ function as defined in the protocol.
Liver function
Adequate organ function as defined in the protocol.
Adequate organ function as defined in the protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Comprehensive Blood and Cancer Center · Bakersfield, California
- City of Hope National Medical Center · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Duarte, California
- University of California San Diego Moores Cancer Center · La Jolla, California
- Translational Research in Oncology US Inc, Trio Central Pharmacy · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify